Truqap is a kinase inhibitor that works by blocking pathways that assistance the cancer cells survive and develop, so lowers cancer growth. Truqap is from a class of medicines referred to as an AKT inhibitor. Truqap acquired FDA approval on November seventeen, 2023, immediately after positive outcomes through the CAPItello-291 https://resmetirom92457.bloggactivo.com/33998283/about-rituximab